The inhibition of Src enhanced the cytotoxicity of cisplatin and paclitaxel in drug-sensitive ovarian cancer cells and restores sensitivity in drug resistant cells, and these effects are dependent on caspase-3 activity [63]. Here, CASP3 is linked to ovarian cancer.